<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">BMJ Open</journal-id><journal-id journal-id-type="iso-abbrev">BMJ Open</journal-id><journal-id journal-id-type="hwp">bmjopen</journal-id><journal-id journal-id-type="publisher-id">bmjopen</journal-id><journal-title-group><journal-title>BMJ Open</journal-title></journal-title-group><issn pub-type="epub">2044-6055</issn><publisher><publisher-name>BMJ Open</publisher-name><publisher-loc>BMA House, Tavistock Square, London, WC1H 9JR</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28473524</article-id><article-id pub-id-type="pmc">5566584</article-id><article-id pub-id-type="publisher-id">bmjopen-2017-015959</article-id><article-id pub-id-type="doi">10.1136/bmjopen-2017-015959</article-id><article-categories><subj-group subj-group-type="heading"><subject>Geriatric Medicine</subject><subj-group><subject>Research</subject></subj-group></subj-group><subj-group subj-group-type="hwp-journal-coll"><subject>1506</subject><subject>1698</subject></subj-group></article-categories><title-group><article-title>A realist evaluation of patients&#x02019; decisions to deprescribe in the EMPOWER trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Martin</surname><given-names>Philippe</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Tannenbaum</surname><given-names>Cara</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<institution content-type="department">Faculty of Pharmacy</institution>, <institution>Universit&#x000e9; de Montr&#x000e9;al</institution>, <addr-line content-type="city">Montreal, Qu&#x000e9;bec</addr-line>, <country>Canada</country>
</aff><aff id="aff2">
<label>2</label>
<institution>Institut Universitaire de G&#x000e9;riatrie de Montr&#x000e9;al</institution>, <addr-line content-type="city">Montreal, Qu&#x000e9;bec</addr-line>, <country>Canada</country>
</aff><aff id="aff3">
<label>3</label>
<institution>Universit&#x000e9; de Montr&#x000e9;al, Faculties of Medicine and Pharmacy</institution>, <addr-line content-type="city">Montreal, Qu&#x000e9;bec</addr-line>, <country>Canada</country>
</aff><author-notes><corresp><label>Correspondence to</label> Philippe Martin; <email>philippe.martin@umontreal.ca</email></corresp></author-notes><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>4</day><month>5</month><year>2017</year></pub-date><volume>7</volume><issue>4</issue><elocation-id>e015959</elocation-id><history><date date-type="received"><day>12</day><month>1</month><year>2017</year></date><date date-type="rev-recd"><day>21</day><month>2</month><year>2017</year></date><date date-type="accepted"><day>8</day><month>3</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link></license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="bmjopen-2017-015959.pdf"/><self-uri content-type="reviewers-comments-pdf" xlink:href="bmjopen-2017-015959.reviewer_comments.pdf"/><self-uri content-type="draft-revisions-pdf" xlink:href="bmjopen-2017-015959.draft_revisions.pdf"/><abstract><sec><title>Background and objectives</title><p>Successful mechanisms for engaging patients in the deprescribing process remain unknown but may include: (1) triggering motivation to deprescribe by increasing patients&#x02019; knowledge and concern about medications; (2) building capacity to taper by augmenting self-efficacy and (3) creating opportunities to discuss and receive support for deprescribing from a healthcare provider. We tested these mechanisms during theEliminating Medications through Patient Ownership of End Results (EMPOWER) () trial and investigated the contexts that led to positive and negative deprescribing outcomes.</p></sec><sec><title>Design</title><p>A realist evaluation using a sequential mixed methods approach, conducted alongside the EMPOWER randomised clinical trial.</p></sec><sec><title>Setting</title><p>Community, Quebec, Canada.</p></sec><sec><title>Participants</title><p>261 older chronic benzodiazepine consumers, who received the EMPOWER intervention and had complete 6-month follow-up data.</p></sec><sec><title>Intervention</title><p>Mailed deprescribing brochure on benzodiazepines.</p></sec><sec><title>Measurements</title><p>Motivation (intent to discuss deprescribing; change in knowledge test score; change in beliefs about the risk&#x02013;benefits of benzodiazepines, measured with the Beliefs about Medicines Questionnaire), capacity (self-efficacy for tapering) and opportunity (support from a physician or pharmacist).</p></sec><sec><title>Results</title><p>The intervention triggered the motivation to deprescribe among 167 (n=64%) participants (mean age 74.6 years&#x000b1;6.3, 72% women), demonstrated by improved knowledge (risk difference, 58.50% (95% CI 46.98% to 67.44%)) and increased concern about taking benzodiazepines (risk difference, 67.67% (95% CI 57.36% to 74.91%)). Those who attempted to taper exhibited increased self-efficacy (risk difference, 56.90% (95% CI 45.41% to 65.77%)). Contexts where the deprescribing mechanisms failed included lack of support from a healthcare provider, a focus on short-term quality of life, intolerance to withdrawal symptoms and perceived poor health.</p></sec><sec><title>Conclusion</title><p>Deprescribing mechanisms that target patient motivation and capacity to deprescribe yield successful outcomes in contexts where healthcare providers are supportive, and patients do not have internal competing desires to remain on drug therapy.</p></sec><sec><title>Trial registration number</title><p>ClinicalTrials.gov: NCT01148186.</p></sec></abstract><kwd-group><kwd>deprescribing</kwd><kwd>benzodiazepines</kwd><kwd>realist evaluation</kwd><kwd>mechanisms</kwd><kwd>EMPOWER</kwd></kwd-group><funding-group><award-group id="funding-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000024</institution-id><institution>Canadian Institutes of Health Research</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>special-feature</meta-name><meta-value>unlocked</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Strengths and limitations of this study</title></caption><list list-type="bullet"><list-item><p>Use of a mixed methods approach enabled us to explore the breadth, depth and complexity of the patient&#x02019;s experience of deprescribing.</p></list-item><list-item><p>Use of the realist evaluation allowed us to investigate how the mechanisms underlying deprescribing interventions interact with specific contexts to yield positive or negative outcomes.</p></list-item><list-item><p>This study was conducted alongside a large cluster randomised clinical trial.</p></list-item></list></boxed-text><sec sec-type="intro" id="s1"><title>Introduction</title><p>Deprescribing refers to the collaborative process of tapering, discontinuing, stopping or withdrawing medications in order to reduce adverse drug events and improve outcomes.<xref rid="R1" ref-type="bibr">1&#x02013;5</xref> Deprescribing has many steps,<xref rid="R1" ref-type="bibr">1 3 6</xref> with one key component being the engagement of patients in shared decision-making.<xref rid="R1" ref-type="bibr">1 7&#x02013;15</xref> Research suggests that older adults have conflicted feelings about medications<xref rid="R4" ref-type="bibr">4 14</xref>: 78% of older adults believe that medications are necessary to improve health, but at the same time, 68% would like to reduce their current medication use, with 92% willing to stop a regular medication if advised to do so by their physician.<xref rid="R14" ref-type="bibr">14</xref> A better understanding of the mechanisms that trigger patient motivation and capacity to engage in the deprescribing process could reduce the use of potentially inappropriate medications.</p><p>The aim of realist evaluation is to reveal how an intervention might generate different outcomes in different circumstances, and how mechanisms work in particular contexts, by enabling or motivating participants to make different choices.<xref rid="R16" ref-type="bibr">16</xref> Educational strategies to increase patients&#x02019; knowledge, beliefs and motivation are hypothesised to influence deliberate action on the part of the patient to curtail the use of a drug.<xref rid="R10" ref-type="bibr">10</xref> However, what works, for whom, under which circumstances and why are questions that have never been explored systematically from the patient&#x02019;s point of view. Recent reviews on deprescribing call for a realist evaluation of large deprescribing trials to investigate how the mechanisms underlying deprescribing interventions interact with specific contexts to yield positive or negative outcomes.<xref rid="R17" ref-type="bibr">17 18</xref> The Eliminating Medications through Patient Ownership of End Results&#x000a0;(EMPOWER) trial, which demonstrated a number-needed-to-treat of 4 for the effectiveness of mailing a benzodiazepine deprescribing brochure on complete cessation of benzodiazepines at 6 months, provides a timely opportunity to examine which deprescribing mechanisms worked under which circumstances.<xref rid="R12" ref-type="bibr">12</xref>
</p><p>The initial theory underpinning the development of the EMPOWER intervention was that most, if not all, older adults are unaware of the age-related harms of taking benzodiazepine anti-anxiety drugs and sleeping pills. Side effects of sedative-hypnotics are well&#x000a0;documented in the literature but rarely talked about in practice as being a potential cause of memory impairment, falls and fractures<xref rid="R19" ref-type="bibr">19&#x02013;24</xref> feared by many older adults.<xref rid="R25" ref-type="bibr">25 26</xref> Not understanding why medications should be discontinued is a patient barrier to deprescribing.<xref rid="R4" ref-type="bibr">4 27</xref> As most patients are uninformed of the potential risks associated with the use of benzodiazepines, we hypothesised a linear behaviour change process whereby providing patients with an interactive educational brochure detailing associated risks, safer alternatives and steps for tapering would trigger patients&#x02019; motivation, capacity and opportunity to initiate the deprescribing process through discussion of medication discontinuation with a healthcare provider.</p><p>This paper reports a realist evaluation of the deprescribing process from the patient&#x02019;s perspective. The realist evaluation tests the following mechanisms: (1) whether the EMPOWER intervention triggered patients&#x02019; motivation to deprescribe by increasing knowledge and concern about benzodiazepines; (2) augmented patients&#x02019; capacity and self-efficacy to taper benzodiazepines and (3) created opportunities for the patient to discuss and receive support from a healthcare provider to engage in the deprescribing process. We also determined in which contexts successful and failed deprescribing outcomes occurred.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Study design</title><p>A realist evaluation was conducted alongside the EMPOWER randomised controlled trial.<xref rid="R12" ref-type="bibr">12</xref> This report follows&#x000a0;online&#x000a0;<xref ref-type="supplementary-material" rid="SP2">supplementary material 2</xref> RAMESES II guidelines for realist evaluation.<xref rid="R16" ref-type="bibr">16</xref> The approach was chosen to inform the implementation of future deprescribing initiatives by examining the possible causes and contextual factors associated with change.<xref rid="R28" ref-type="bibr">28</xref> Realist evaluation is a theory-based, sequential mixed methods approach that seeks to gain a deeper understanding of contexts, mechanisms and outcomes. This is accomplished through the identification and examination of underlying generative mechanisms (M) associated with the intervention or programme, the conditions or contexts (C) under which the mechanisms operate, and the pattern of outcomes (O) produced. These may be expressed as linked Contexts&#x02013;Mechanisms&#x02013;Outcomes configurations (or C+M=O).<xref rid="R28" ref-type="bibr">28</xref> In this case, the (C) consist of all internal and external factors that can influence the deprescribing process and the (O) refer to whether or not the deprescribing intervention was successful. The (M) that we aimed to test were whether the EMPOWER brochure: (1) triggered older adults&#x02019; motivation to deprescribe by increasing knowledge and concern about benzodiazepines; (2) built capacity to taper by augmenting self-efficacy and (3) drove opportunities to receive support from a healthcare provider to deprescribe.</p><supplementary-material content-type="local-data" id="SP2"><object-id pub-id-type="doi">10.1136/bmjopen-2017-015959.supp2</object-id><caption><title>Supplementary data</title></caption><p>
<inline-supplementary-material id="ss2" xlink:href="bmjopen-2017-015959supp001.docx" mimetype="application" mime-subtype="docx" content-type="local-data"/>
</p></supplementary-material><p>The study was approved by the Institut Universitaire de G&#x000e9;riatrie de Montr&#x000e9;al Ethics Committee in Montreal, Quebec, Canada.</p></sec><sec id="s2b"><title>Environment surrounding the evaluation</title><p>The EMPOWER trial was a pragmatic randomised trial that examined the effectiveness of a direct-to-consumer, written educational brochure mailed directly to patients on subsequent discontinuation of sedative-hypnotic medication.<xref rid="R29" ref-type="bibr">29</xref> The EMPOWER trial was rolled out between July 2010 and November 2013, with community-dwelling participants randomly recruited via pharmacists located within a 200&#x02009;km radius of the Montreal urban area in Quebec, Canada. Participants were 303 older, community-dwelling, chronic users of benzodiazepine medication and agreed to home visits and telephone follow-up interviews by the research team. All benzodiazepine prescriptions for seniors were covered under the publicly financed drug plan in the province of Quebec, excluding the programme&#x02019;s deductible (if applicable). Provincial governments covered physician reimbursements for patient visits, and drug dispensing fees for pharmacists, as part of Canada&#x02019;s universal healthcare programme.</p></sec><sec id="s2c"><title>The EMPOWER intervention</title><p>The eight-page EMPOWER brochure, available at <ext-link ext-link-type="uri" xlink:href="http://www.criugm.qc.ca/fichier/pdf/BENZOeng.pdf">http://www.criugm.qc.ca/fichier/pdf/BENZOeng.pdf</ext-link>,<xref rid="R30" ref-type="bibr">30</xref> aims to promote active learning by incorporating and using constructivist learning principles.<xref rid="R31" ref-type="bibr">31</xref> The brochure includes a self-assessment component and presentation of the evidence-based risks associated with benzodiazepine use in an effort to elicit cognitive dissonance.<xref rid="R10" ref-type="bibr">10</xref> Elements of social comparison theory,<xref rid="R32" ref-type="bibr">32</xref> through the use of peer champion stories, are also integrated in the intervention. The brochure provides a self-guided tapering schedule, consisting of a visual tapering protocol showing pictures of full pills, halved pills and quartered pills.<xref rid="R30" ref-type="bibr">30</xref>
</p></sec><sec id="s2d"><title>Evaluation of mechanisms and contexts</title><p>The mechanisms embedded in the EMPOWER intervention are based on Michie <italic>et al</italic>&#x02019;s behaviour change wheel,<xref rid="R33" ref-type="bibr">33</xref> targeting motivation, capacity and opportunity. Michie <italic>et al</italic> define motivation as the mental process that energises and directs behaviours. Capability refers to the psychological and physical capacity of the individual to engage in the behaviour. Opportunity refers to the internal and external factors that permit or promote a behaviour to happen, and include both the physical and social environment of the individual. <xref ref-type="table" rid="T1">Table 1</xref> links the programme mechanisms to the corresponding intervention components.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Programme mechanisms embedded in EMPOWER intervention</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left" rowspan="1" colspan="1">
<bold>Mechanisms</bold>
</td><td colspan="3" rowspan="1">
<bold>Components of the EMPOWER brochure</bold>
</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Increase motivation to deprescribe by changing knowledge and beliefs</td><td align="left" rowspan="1" colspan="1">Messaging on the front page <break/>&#x02018;You May be at Risk&#x02019; to raise awareness of the harms of benzodiazepines</td><td align="left" rowspan="1" colspan="1">Interactive knowledge test with four true/false questions and answers about the harms of benzodiazepines, aimed at increasing knowledge</td><td align="left" rowspan="1" colspan="1">Information about changes in drug metabolism with age that can lead to a higher risk of side effects, meant to change beliefs and elicit concern about the safety of the medication in older adults</td></tr><tr><td align="left" rowspan="1" colspan="1">Increase capacity to taper by augmenting self-efficacy</td><td align="left" rowspan="1" colspan="1">A list of alternative non-pharmacological approaches to sleep and anxiety that patients can use as substitutes</td><td align="left" rowspan="1" colspan="1">An inspirational story using social comparison and peer championing to increase self-efficacy for tapering</td><td align="left" rowspan="1" colspan="1">Provision of an easy-to-use visual 16&#x02013;20&#x02009;weeks tapering tool showing when to take a whole, half or quarter pill, and when to skip the dose completely</td></tr><tr><td align="left" rowspan="1" colspan="1">Drive opportunities to discuss and initiate deprescribing with a healthcare provider</td><td align="left" rowspan="1" colspan="1">Instruction to &#x02018;Please consult your doctor or pharmacist before stopping any medication&#x02019; in a large red box</td><td align="left" rowspan="1" colspan="1">Logos on the brochure provide source credibility for the patient to initiate conversations</td><td align="left" rowspan="1" colspan="1">The printed format of the eight-page brochure makes it an effective knowledge transfer piece to take and show to a healthcare provider</td></tr></tbody></table></table-wrap><p>The evaluation of mechanisms and contexts consisted of quantitative data collection and analysis, qualitative data collection and analysis and triangulation of the quantitative and qualitative results.<xref rid="R34" ref-type="bibr">34</xref> Data collection was conducted between July 2010 and November 2013 as part of the EMPOWER clinical trial. Analysis, triangulation and refinement of the Context&#x02013;Mechanism&#x02013;Outcome configuration took place subsequent to completion of the trial.</p></sec><sec id="s2e"><title>Data collection methods</title><p>Quantitative data included preintervention and 1-week postintervention information on knowledge about benzodiazepine-related harms, beliefs about the necessity of taking benzodiazepines versus concern about harms, self-efficacy for tapering and intent to discuss deprescribing with a healthcare provider. We measured gains in knowledge with the four true or false questions listed in the &#x02018;Test Your Knowledge&#x02019; section of the questionnaire.<xref rid="R29" ref-type="bibr">29 30</xref> Correct answers were summed to a maximum of 4 points, and answers were compared prior to and after receiving the intervention. Participants&#x02019; beliefs about consuming benzodiazepines were measured with the Beliefs about Medicines Questionnaire (BMQ-Specific) at both time points. The BMQ-Specific consists of two validated five-item subscales assessing the respondents&#x02019; perceptions about the necessity and concerns associated with taking benzodiazepines.<xref rid="R35" ref-type="bibr">35</xref> Participants indicate their degree of agreement with each statement on a five-point Likert scale (1=strongly disagree, 5=strongly agree). Scores are summed into their respective subcategory (5&#x02013;25 point scale) with higher scores indicating stronger beliefs. Risk perception was assessed using a single question 1-week postintervention in which participants were asked whether they perceived the same, increased or no risk from consumption of their benzodiazepine following the intervention. In order to determine whether the EMPOWER brochure increased capacity to taper by augmenting self-efficacy, we measured self-efficacy for tapering on the Medication Reduction Self-efficacy scale, which allows the respondent to rate on a scale of 0 to 100 their degree of confidence for tapering benzodiazepines.<xref rid="R36" ref-type="bibr">36</xref> Higher scores indicate greater self-efficacy. Participants were also asked to indicate (yes/no) postintervention if they had spoken to or intended to discuss medication discontinuation with their doctor and/or pharmacist. Health status was assessed at baseline using the first item of the Short-Form-12 Health Survey and dichotomised by categorising poor to fair responses as poor health.<xref rid="R37" ref-type="bibr">37</xref>
</p><p>Qualitative data were collected after the 6-month follow-up, using semistructured interviews conducted at participants&#x02019; homes to determine the contexts under which the deprescribing mechanisms succeeded or failed. Twenty-one participants were strategically sampled for the interviews using a contrast sample design, based on cessation of benzodiazepines (yes or no) combined with intent to discuss tapering (yes or no).<xref rid="R38" ref-type="bibr">38</xref> Interviews lasted approximately 1&#x02009;hour, were recorded with consent and professionally transcribed verbatim. The interviews were based on a pre-established discussion guide, the major themes of which included initial reactions to the intervention, reasons underlying the decision to taper, experience with the tapering process and personal interactions with healthcare providers (see&#x000a0;online&#x000a0;<xref ref-type="supplementary-material" rid="SP1">supplementary material 1)</xref>.</p><supplementary-material content-type="local-data" id="SP1"><object-id pub-id-type="doi">10.1136/bmjopen-2017-015959.supp1</object-id><caption><title>Supplementary data</title></caption><p>
<inline-supplementary-material id="ss1" xlink:href="bmjopen-2017-015959supp002.pdf" mimetype="application" mime-subtype="pdf" content-type="local-data"/>
</p></supplementary-material></sec><sec id="s2f"><title>Analysis</title><p>The three mechanisms of increasing motivation, capacity and opportunity were tested using quantitative analysis. Participants with complete follow-up data were included in the quantitative analysis (n=261, mean age 74.6&#x000b1;6.3, 72% women). Data were described and compared using means with SD and independent t-tests for continuous data, and percentages and &#x003c7;<sup>2</sup>&#x000a0;tests for categorical data, according to each of three outcomes: intent to deprescribe with successful discontinuation, intent to deprescribe with failed discontinuation and no intent to deprescribe. Individuals who achieved a dose reduction were classified as intent to deprescribe with failed discontinuation. Participant changes in knowledge, in the BMQ necessity and concerns subscales and in self-efficacy scores for tapering were computed from baseline to postintervention. Risk differences with 95% CIs were calculated for the proportion of participants in each group who demonstrated increased knowledge, heightened concern about benzodiazepine use and augmented self-efficacy for tapering. The statistical significance for all analyses was set at p&#x0003c;0.05 (two-sided).<xref rid="R39" ref-type="bibr">39</xref> SPSS V.21.0 was used for all analyses.</p><p>Qualitative data from the semistructured interviews were analysed using thematic content analysis to explore the contexts under which the programme mechanisms led to positive or negative outcomes.<xref rid="R40" ref-type="bibr">40</xref> Discourses were contrasted according to whether participants discontinued benzodiazepines and/or expressed the intent to discuss discontinuation. Interviews were coded using Dedoose software. Contextual themes were derived from the data and supported by quotes. Initially, two researchers independently read the transcripts and field notes, then collaboratively developed first order codes, which were subsequently verified by double coding. Second order thematic coding was performed for the purpose of building concepts.</p><p>Quantitative and qualitative results about context were combined and analysed in an iterative fashion through use of a triangulation protocol using a convergence coding matrix,<xref rid="R41" ref-type="bibr">41</xref> as described by Farmer <italic>et al</italic>.<xref rid="R42" ref-type="bibr">42</xref> The convergence matrix served to inform which contexts favourably or unfavourably influenced a patient&#x02019;s decision to deprescribe based on agreement, partial agreement or dissonance between the quantitative and qualitative data.<xref rid="R41" ref-type="bibr">41 42</xref> Differences were adjudicated via discussion and consensus.<xref rid="R42" ref-type="bibr">42</xref> The convergence-coding matrix is available from the authors on request.</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec id="s3a"><title>Linking mechanisms to outcomes</title><p>The mechanism of triggering motivation to deprescribe occurred in 167 of 261 individuals (64%) who received the EMPOWER intervention (<xref ref-type="table" rid="T2">table 2</xref>).Participants who expressed an intent to deprescribe postintervention had improved knowledge (risk difference, 58.50% (95% CI 46.98% to 67.44 %)), lower perceived necessity scores (risk difference, 56.03% (95% CI 44.63% to 64.81%)), increased concern (risk difference, 67.67% (95% CI 57.36% to 74.91%)) and a greater perception of risk about their benzodiazepine medication than those who were not motivated to attempt deprescribing (risk difference, 35.14% (95% CI 23.06% to 45.39%)). Individuals who decided to deprescribe exhibited higher capacity for tapering after receipt of the EMPOWER brochure, with enhanced self-efficacy compared with those in whom the intervention did not trigger motivation (risk difference, 56.90% (95% CI 45.41% to 65.77%)) (<xref ref-type="table" rid="T2">table 2</xref>). Approximately half of individuals with augmented motivation and capacity to deprescribe initiated a conversation with their physician, and 25% spoke to a pharmacist about deprescribing. Neither postintervention self-efficacy scores nor creating the opportunity to discuss deprescribing with a healthcare provider distinguished between positive or negative outcomes among motivated individuals.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Linking mechanisms to outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><td valign="top" rowspan="2" align="left" colspan="1">Mechanisms</td><td valign="top" colspan="6" align="left" rowspan="1">
<bold>Outcomes</bold>
</td></tr><tr><th align="left" rowspan="1" colspan="1">All (n=261)</th><th align="left" rowspan="1" colspan="1">Successful deprescribing&#x000a0; <break/>(n=92)</th><th align="left" rowspan="1" colspan="1">Intent but failed deprescribing (n=75)</th><th align="left" rowspan="1" colspan="1">No attempt to deprescribe (n=94)</th><th align="left" rowspan="1" colspan="1">Successful and failed intent versus no attempt* p value/risk difference (95%&#x02009;CI)</th><th align="left" rowspan="1" colspan="1">Successful completion versus failed intent to deprescribe p value/risk difference (95%&#x02009;CI)</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Increased motivation</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Change in knowledge:</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Baseline knowledge (/4), mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">0.85 (0.99)</td><td valign="top" align="left" rowspan="1" colspan="1">0.97 (1.08)</td><td valign="top" align="left" rowspan="1" colspan="1">0.87 (0.97)</td><td valign="top" align="left" rowspan="1" colspan="1">0.71 (0.90)</td><td valign="top" align="left" rowspan="1" colspan="1">0.10</td><td valign="top" align="left" rowspan="1" colspan="1">0.54</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Postintervention knowledge (/4), mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">1.92 (1.40)</td><td valign="top" align="left" rowspan="1" colspan="1">2.64 (1.23)</td><td valign="top" align="left" rowspan="1" colspan="1">2.01 (1.34)</td><td valign="top" align="left" rowspan="1" colspan="1">1.13 (1.20)</td><td valign="top" align="left" rowspan="1" colspan="1">0.00*</td><td valign="top" align="left" rowspan="1" colspan="1">0.00*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Increase in knowledge postintervention, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">156 (59.8)</td><td valign="top" align="left" rowspan="1" colspan="1">80 (86.9)</td><td valign="top" align="left" rowspan="1" colspan="1">55 (73.3)</td><td valign="top" align="left" rowspan="1" colspan="1">21 (22.3)</td><td valign="top" align="left" rowspan="1" colspan="1">58.5 (47.0 to 67.4)*</td><td valign="top" align="left" rowspan="1" colspan="1">13.6 (1.6 to 25.9)*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Beliefs about benzodiazepines</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Baseline belief about necessity&#x02020; (/25), mean score (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">13.8 (3.4)</td><td valign="top" align="left" rowspan="1" colspan="1">13.0 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">14.3 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">14.1 (0.4)</td><td valign="top" align="left" rowspan="1" colspan="1">0.23</td><td valign="top" align="left" rowspan="1" colspan="1">0.01*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Postintervention belief about necessity&#x02020;, mean score (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">12.58 (3.32)</td><td valign="top" align="left" rowspan="1" colspan="1">11.07 (0.30)</td><td valign="top" align="left" rowspan="1" colspan="1">12.55 (0.32)</td><td valign="top" align="left" rowspan="1" colspan="1">14.05 (0.35)</td><td valign="top" align="left" rowspan="1" colspan="1">0.00*</td><td valign="top" align="left" rowspan="1" colspan="1">0.10</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Participants with a decrease in score about necessity postintervention, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">138 (52.8)</td><td valign="top" align="left" rowspan="1" colspan="1">75 (81.5)</td><td valign="top" align="left" rowspan="1" colspan="1">47 (62.7)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (17.4)</td><td valign="top" align="left" rowspan="1" colspan="1">56.0 (44.6 to 64.8)*</td><td valign="top" align="left" rowspan="1" colspan="1">18.9 (5.3 to 32.0)*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Baseline concern&#x02020;, (/25), mean score (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">13.4 (2.7)</td><td valign="top" align="left" rowspan="1" colspan="1">13.4 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">14.1 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">12.9 (0.3)</td><td valign="top" align="left" rowspan="1" colspan="1">0.00*</td><td valign="top" align="left" rowspan="1" colspan="1">0.01*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Postintervention concern&#x02020;, mean score (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">14.42 (3.41)</td><td valign="top" align="left" rowspan="1" colspan="1">15.60 (0.37)</td><td valign="top" align="left" rowspan="1" colspan="1">15.34 (0.36)</td><td valign="top" align="left" rowspan="1" colspan="1">12.56 (0.28)</td><td valign="top" align="left" rowspan="1" colspan="1">0.00*</td><td valign="top" align="left" rowspan="1" colspan="1">0.62</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Participants with increased concern postintervention, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">138 (52.8)</td><td valign="top" align="left" rowspan="1" colspan="1">70 (76.1)</td><td valign="top" align="left" rowspan="1" colspan="1">59 (78.7)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (9.7)</td><td valign="top" align="left" rowspan="1" colspan="1">67.7 (57.3 to 74.9)*</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.6 (&#x02212;15.0 to 10.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Risk perception:</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Participants perceiving increased risk postintervention, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">118 (44.8)</td><td valign="top" align="left" rowspan="1" colspan="1">51 (55.4)</td><td valign="top" align="left" rowspan="1" colspan="1">45 (60.0)</td><td valign="top" align="left" rowspan="1" colspan="1">21 (22.3)</td><td valign="top" align="left" rowspan="1" colspan="1">35.1 (23.1 to 45.4)*</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;4.6 (&#x02212;19.1 to 10.4)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Building capacity</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Self-efficacy for tapering</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Baseline self-efficacy (/100), mean (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">37.8 (35.7)</td><td valign="top" align="left" rowspan="1" colspan="1">47.3 (34.6)</td><td valign="top" align="left" rowspan="1" colspan="1">35.0 (37.4)</td><td valign="top" align="left" rowspan="1" colspan="1">31.0 (33.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0.03*</td><td valign="top" align="left" rowspan="1" colspan="1">0.02*</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Postintervention increase in self-efficacy score, mean change (SD)</td><td valign="top" align="left" rowspan="1" colspan="1">25.44 (42.78)</td><td valign="top" align="left" rowspan="1" colspan="1">35.78&#x000a0;(36.80)</td><td valign="top" align="left" rowspan="1" colspan="1">36.03 (44.63)</td><td valign="top" align="left" rowspan="1" colspan="1">6.00&#x000a0;(40.93)</td><td valign="top" align="left" rowspan="1" colspan="1">0.00*</td><td valign="top" align="left" rowspan="1" colspan="1">0.97</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Participants with increased self-efficacy postintervention, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">145 (55.5)</td><td valign="top" align="left" rowspan="1" colspan="1">70 (76.1)</td><td valign="top" align="left" rowspan="1" colspan="1">57 (76.0)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (19.1)</td><td valign="top" align="left" rowspan="1" colspan="1">56.9 (45.4 to 65.8)*</td><td valign="top" align="left" rowspan="1" colspan="1">0 (&#x02212;12.6 to 13.3)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<italic>Creating opportunity</italic>
</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Outreach to a healthcare professional:</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Discussed with physician, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">103 (39.5)</td><td valign="top" align="left" rowspan="1" colspan="1">42 (45.6)</td><td valign="top" align="left" rowspan="1" colspan="1">38 (50.6)</td><td valign="top" align="left" rowspan="1" colspan="1">23 (25.0)</td><td valign="top" align="left" rowspan="1" colspan="1">23.4 (11.3 to 34.1)*</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;5.0 (&#x02212;19.8 to 10.0)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Discussed with pharmacist, n (%)</td><td valign="top" align="left" rowspan="1" colspan="1">56 (20.1)</td><td valign="top" align="left" rowspan="1" colspan="1">25 (27.1)</td><td valign="top" align="left" rowspan="1" colspan="1">22 (28.9)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (9.7)</td><td valign="top" align="left" rowspan="1" colspan="1">18.6 (8.7 to 27.1)*</td><td valign="top" align="left" rowspan="1" colspan="1">&#x02212;2.2 (&#x02212;15.9 to 11.3)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><p>*Level of significance, p&#x0003c;0.05.</p></fn><fn id="tblfn2"><p>&#x02020;As some participants selected more than one condition, total does not equal 100%.</p></fn><fn id="tblfn3"><p>Independent sample t-test for continuous variables, &#x003c7;<sup>2</sup> for categorical variables.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Contexts associated with positive deprescribing outcomes</title><p>
<xref ref-type="table" rid="T3">Table 3</xref> shows the results of the qualitative analysis, describing the contexts that enabled the EMPOWER mechanisms to achieve positive deprescribing outcomes. Favourable personal contexts included stable health status and a positive outlook on ageing. Individuals who were not dealing with acute health issues were more receptive to tapering off benzodiazepines, as were individuals who prioritised long life expectancy over the short-term benefits of continued use or the transient discomfort associated with deprescribing benzodiazepines. Individuals who succeeded in tapering had the highest baseline self-efficacy for being able to discontinue (<xref ref-type="table" rid="T2">table 2</xref>). External influences associated with successful discontinuation were previous and ongoing support or encouragement from a healthcare provider (<xref ref-type="table" rid="T3">table 3</xref>).</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Contexts associated with positive outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" colspan="4" align="char" char="(" rowspan="1">
<bold>Outcomes</bold>
</td></tr><tr><th rowspan="1" colspan="1">Contexts</th><th rowspan="1" colspan="1">Successful deprescribing (n=7)</th><th rowspan="1" colspan="1">Failed deprescribing (n=7)</th><th rowspan="1" colspan="1">No attempt to deprescribe (n=7)</th><th rowspan="1" colspan="1">Supporting citation</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Previous support from physician/positive attitude towards discontinuation</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">5 (71%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">4 (57%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">1 (14%)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;He (my doctor) told me the drug was not good for me and that I could experience side effects while taking it&#x02019;.&#x000a0;</italic>(72-year-old man, successful taper)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Stable health status</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">5 (71%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">4 (57%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">2 (29%)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;I don&#x02019;t have as much pain as I used to. It&#x02019;s now under control so it was easier for me to stop. Before&#x02014;no way&#x02019;.</italic> (68-year-old woman, successful taper)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Certainty and confidence about tapering (postintervention)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">6 (86%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">4 (57%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">1 (14%)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;I persuaded myself that I needed to get rid of this, no matter what</italic>&#x02019;. (84-year-old man, successful taper)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Perception of increased risk</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">6 (86%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">5 (71%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">1 (14%)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;My physician told me it (the drugs) could cost me my memory. My memory has become very important to me&#x02019;.&#x000a0;</italic>(79-year-old man, successful taper)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lack of psychological attachment</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">5 (71%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">3 (43%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">1 (14%)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;I understood I could stop taking it (after I read the brochure), that it was not an obligation (to take it)</italic>&#x02019;.&#x000a0;(72-year-old woman, successful taper)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Positive outlook on ageing</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">3 (43%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">1 (14%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;At my age I don&#x02019;t believe in miracles such as being able to sleep for 8, 9 or 10&#x02009;hours each night. It would be impossible for me, so I content myself with the hours of sleep I get&#x02019;.</italic> (84-year-old man, successful taper)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Tapering tool provides support</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">5 (71%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">3 (43%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;In the past I tried to stop the pill all at once. But using the tapering tool, I understood that it need to be a gradual and not a drastic process&#x02019;.</italic> (84-year-old man, successful taper)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Supportive healthcare provider</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">3 (43%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">2 (29%)</td><td valign="top" align="char" char="(" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;When I told my doctor I wanted to stop, he said, &#x02018;no problem, let&#x02019;s do it&#x02019;.</italic> (87-year-old woman, successful taper)</td></tr></tbody></table></table-wrap></sec><sec id="s3c"><title>Contexts in which the EMPOWER mechanisms failed</title><p>Thirty-six per&#x000a0;cent of the participants in the trial reported no desire to deprescribe after receipt of the EMPOWER brochure. These individuals showed no gain in knowledge and no increase in perceived risk post-intervention (<xref ref-type="table" rid="T2">table 2</xref>). Failure for the EMPOWER intervention to elicit motivation to deprescribe was more likely among individuals who reported poor health (40% vs 28%, 12.28% (95% CI 0.44% to 24.18%)). During the qualitative interviews, participants dealing with ongoing health issues expressed a strong reliance on benzodiazepines for everyday coping (<xref ref-type="table" rid="T4">table 4</xref>). Other contexts associated with the decision not to attempt deprescribing included previous reassurance by a physician that benzodiazepines were safe or necessary and the belief that the benefits of benzodiazepines outweighed the risks for immediate symptom relief (<xref ref-type="table" rid="T4">table 4</xref>). Contexts that led participants to abort the deprescribing process once they showed initial motivation, capacity and opportunity to deprescribe included the lack of support from a healthcare provider, intolerance to withdrawal symptoms and a sudden loss of confidence to live without sleeping pills (<xref ref-type="table" rid="T4">table 4</xref>).</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><p>Contexts associated with negative outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Key theme</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Successful deprescribing (n=7)</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Failed deprescribing (n=7)</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>No attempt to deprescribe</bold>
<break/>
<bold>(n=7)</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Supporting citation</bold>
</td></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Previous discouragement from physician</td><td valign="top" align="left" rowspan="1" colspan="1">1 (14%)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (14%)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (71%)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;I asked him (my doctor), &#x02018;Are there any of my medications I could stop?&#x02019; He told me, &#x02018;No, we&#x02019;re not taking anything away, you are doing well&#x02019;. I then told him my medication was getting very expensive to which he replied, &#x02018;You know Mr., life is priceless&#x02019;.</italic> (75-year-old man, no intent to taper)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Poor health status</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">1 (14%)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (57%)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;If anyone stops my pills, poof, I would die for sure because of my poor health&#x02019;.</italic> (70-year-old woman, no intent to taper)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Unquestioning belief in their physician</td><td valign="top" align="left" rowspan="1" colspan="1">1 (14%)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (14%)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (43%)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;If you take all your pills as prescribed, you&#x02019;ll never have problems in your life [&#x02026;] When my doctor prescribes something for me, I know it&#x02019;s not junk, I know it&#x02019;s good for me. And I don&#x02019;t question it&#x02019;.</italic> (72-year-old man, no intent to taper)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Lack of perception of personal risk</td><td valign="top" align="left" rowspan="1" colspan="1">1 (14%)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (29%)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (71%)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;I recall that he (my doctor) told me that in the long-term my benzodiazepine could affect my memory. But my memory is fantastic&#x02019;.</italic> (72-year-old man, no intent to taper)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Reliance on medication for coping/everyday function</td><td valign="top" align="left" rowspan="1" colspan="1">1 (14%)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (14%)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (57%)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;Without this medication, I know that my life would be plagued by anxiety, of this I am certain&#x02019;.</italic> (68-year-old woman, no intent to taper)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Quality of life focus during end&#x000a0;of life</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">2 (29%)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (43%)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;At my age I don&#x02019;t care about the risks. I don&#x02019;t care if I live to 100 or not&#x02019;.</italic> (85-year-old woman, failed tapering)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Discouragement from a physician</td><td valign="top" align="left" rowspan="1" colspan="1">1 (14%)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (43%)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (71%)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;My doctor told me: &#x02018;At your age, don&#x02019;t worry about it. You&#x02019;ve been taking this pill for a while and you are fine. You aren&#x02019;t taking a dangerous dose at all</italic>&#x02019;. (85-year-old woman, failed tapering)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Intolerance to recurrence of symptoms/withdrawal effects</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">5 (71%)</td><td valign="top" align="left" rowspan="1" colspan="1">_</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;When I decreased the dose I started getting headaches. I felt miserable not being able to sleep at night&#x02019;.</italic> (85-year-old man, failed tapering)</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Loss of confidence to complete the tapering process (postintervention)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">4 (57%)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (57%)</td><td valign="top" align="left" rowspan="1" colspan="1">
<italic>&#x02018;I knew that I&#x02019;d be in trouble without my pills. It&#x02019;s been a long time now. How can I put it in words? If I ran out of pills I&#x02019;d be in trouble&#x02019;.</italic> (85-year-old man, failed tapering)</td></tr></tbody></table></table-wrap></sec><sec id="s3d"><title>Refining the context&#x02013;mechanism&#x02013;outcome configuration for deprescribing interventions</title><p>The initial context&#x02013;mechanism&#x02013;outcome configuration that drove the development of the EMPOWER intervention was a simple, linear progression along different stages of readiness to deprescribe, similar to Prochaska &#x00026; DiClemente&#x02019;s transtheoretical model of change (<xref ref-type="fig" rid="F1">figure 1A</xref>).<xref rid="R43" ref-type="bibr">43</xref> We believed that the EMPOWER brochure would trigger motivation and capacity to deprescribe, moving patients from precontemplation about deprescribing to action and maintenance, by increasing knowledge about the harms of benzodiazepines, enhancing self-efficacy and creating opportunities to discuss deprescribing with a healthcare professional. We assumed that&#x000a0;the healthcare provider would provide a supportive context, encouraging the patient to deprescribe, thereby yielding a positive outcome. This initial configuration oversimplified the stages through which individuals transitioned after receiving the deprescribing intervention. <xref ref-type="fig" rid="F1">Figure 1B</xref> depicts a revised, non-linear context&#x02013;mechanism&#x02013;outcome configuration that takes into account the complexity of internal and external contexts on initiating and completing the deprescribing process from the consumer&#x02019;s perspective. The revised model recognises that new information influences beliefs and actions only if the information generates a desire strong enough not to be overwhelmed by competing motivations arising from other sources. In many instances, the desire for risk reduction, which was the prime motivator behind the development of the EMPOWER intervention, did not supersede concerns about symptom recurrence, or other psychological and health factors, as well as interpersonal relationships with healthcare providers, which played critical contextual roles in the outcome of the intervention.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>(A) Initial deprescribing context&#x02013;mechanism&#x02013;outcome configuration. (B) Refined deprescribing context&#x02013;mechanism&#x02013;outcome configuration.</p></caption><graphic xlink:href="bmjopen-2017-015959f01"/></fig></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>This realist evaluation tested the mechanisms embedded in the EMPOWER intervention and showed that motivation and capacity to deprescribe were triggered in 64% of older chronic benzodiazepines consumers, the majority of whom created an opportunity to discuss deprescribing with a healthcare provider. These findings support the theory that provision of new knowledge about medication harms can raise concern and augment patients&#x02019; self-efficacy to deprescribe. However, the analysis also indicates that human motivation to deprescribe is complex and unstable. A variety of internal and external contexts can interfere with the decision to deprescribe. Internal influences include perceptions about one&#x02019;s health status, long-term health goals, fear of symptom recurrence and psychological attachment to the drug. The main external influence that blocks consumer-directed deprescribing mechanisms is the lack of support from a healthcare provider.</p><p>Our findings contribute to the literature by illustrating that linear progression along different stages of readiness to deprescribe does not fully explain successful deprescribing from the patient&#x02019;s perspective. This conclusion is consistent with other critiques of the transtheoretical model, which claim that the stages of readiness are arbitrary, that human beings do not make logical and stable plans to change their behaviour and that setbacks can occur along the trajectory of change.<xref rid="R44" ref-type="bibr">44</xref> Education appears to be necessary but insufficient for many individuals, and new strategies will be needed to trigger deprescribing in prohibitive contexts where the EMPOWER mechanisms failed. As capacity and motivations change over time, reminders and ongoing discussions about the risks of inappropriate medications may progressively trigger and sustain patients&#x02019; commitments to engage in the deprescribing process. Some competing factors may wane, such as poor health. Offering cognitive behavioural therapy to patients during the most difficult last quarter period of the tapering protocol may augment self-efficacy for overcoming withdrawal symptoms.<xref rid="R36" ref-type="bibr">36</xref> Interventions can be directed at healthcare providers who discourage deprescribing efforts. Continuing medical education to inform health providers about the mounting evidence on the harms of benzodiazepine use may curtail the phenomenon of physicians who continue to promote the use of inappropriate medication.<xref rid="R20" ref-type="bibr">20 45</xref> Future research directions should also include measurement of cognitive dissonance, which lies at the heart of constructivist learning.<xref rid="R46" ref-type="bibr">46</xref> Methods to measure cognitive dissonance, defined as a feeling of tension between two sets of competing beliefs and motivations, may shed light on the way in which tensions about deprescribing are played out and drive behaviour change.<xref rid="R46" ref-type="bibr">46 47</xref> As we did not directly ask patients if they felt internal tension, we were unable to record feelings or processes of cognitive dissonance.</p><p>Use of a mixed methods approach enabled us to explore the breadth, depth and complexity of the patient&#x02019;s experience of deprescribing from a social, behavioural and health perspective, allowing stronger inferences about the various contexts affecting patients&#x02019; decisions than could be achieved through a quantitative or qualitative lens alone.<xref rid="R48" ref-type="bibr">48</xref> However, other mechanisms and contexts may trigger motivation to deprescribe beyond what is described in this realist evaluation. One untested mechanism is provision of information about the lack of drug benefits in certain populations, such as statins to reduce cholesterol levels in palliative care patients with limited life expectancy.<xref rid="R49" ref-type="bibr">49 50</xref> Another challenge that we experienced during the conduct of this realist evaluation was differentiating between the mechanisms and contexts associated with deprescribing.<xref rid="R51" ref-type="bibr">51</xref> For instance, when participants stated that their physician or pharmacist undermined their decision to deprescribe, it was clear this factor changed the reasoning of the participants. However, we were not sure whether this factor should be labelled as a mechanism or a context. Since the mechanism of action is defined as the &#x02018;how&#x02019; behind the generation of outcomes, we initially thought that healthcare provider support was a mechanism that brought about deprescribing.<xref rid="R51" ref-type="bibr">51</xref>&#x000a0;On iterative reflection and discussion of the C&#x02013;M&#x02013;O configurations, we came to the conclusion that healthcare provider support was actually a context that enabled or hindered the consumer&#x02019;s motivation, capacity and opportunity to deprescribe, as triggered by the EMPOWER intervention. We drew this conclusion by subscribing to Pawson and Tilley&#x02019;s initial approach to realist evaluation, which seeks to identify mechanisms at the level of the individual&#x02019;s human reasoning.<xref rid="R52" ref-type="bibr">52</xref> Others such as Dalkin <italic>et al</italic> posit that interpersonal relationships between stakeholders are a key factor that influence human reasoning, and argue that mechanisms can also be evaluated through the social lens of human and systems interactions.<xref rid="R51" ref-type="bibr">51</xref> Deprescribing in particular is a complex social process that involves patients, prescribers and pharmacists, so our analysis may be faulted by some for studying the consumer&#x02019;s decision-making processes in isolation. For this reason, we chose not to make a table listing discrete C&#x02013;M&#x02013;O relationships in this paper but instead focused on broadly describing and testing the mechanisms embedded in the EMPOWER intervention and outlining the different personal, interpersonal and external contexts that led to positive or negative outcomes. We created <xref ref-type="fig" rid="F1">figure 1A,B</xref> with difficulty, and some scepticism about whether these complex interactions could be illustrated in simple form. As the field of realist evaluation evolves, new terminology and formats may emerge that better capture a way of graphically illustrating the science of human interactions and behaviour change.</p><p>In conclusion, this realist evaluation conducted alongside a clinical trial provides important insights about deprescribing from the patient&#x02019;s perspective and increases current understanding about the specific mechanisms and contexts that generate positive or negative outcomes when attempting to engage patients in curbing the overuse and potentially inappropriate use of medicines.</p></sec><sec sec-type="supplementary-material"><title>Supplementary Material</title><supplementary-material id="d35e165" content-type="local-data"><caption><title>Reviewer comments</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="bmjopen-2017-015959.reviewer_comments.pdf"/></supplementary-material><supplementary-material id="d35e166" content-type="local-data"><caption><title>Author's manuscript</title></caption><media mimetype="application" mime-subtype="pdf" xlink:href="bmjopen-2017-015959.draft_revisions.pdf"/></supplementary-material></sec></body><back><ack id="ack"><p>We wish to acknowledge the work of Anne-Sophie Michaud and Anastasia Soboleva who conducted the in-home interviews and helped in identifying first order coding for the qualitative portion of the manuscript. Additionally, we would like to thank Johanne Collin for her advice in devising the general strategy for the qualitative interviews. We express gratitude to all the participants and pharmacists who took part in this trial. Particular thanks are offered to the Pharmacy Services Department of the Jean Coutu Group (PJC) Inc. for their collaboration and support.</p></ack><fn-group><fn fn-type="other"><p><bold>Contributors:</bold> PM and CT contributed to the study concept and design, analysis and interpretation of data, drafting of the manuscript, critical revision of the manuscript for important intellectual content and final approval of the version to be published.</p></fn><fn fn-type="other"><p><bold>Funding:</bold> This work was supported by Operating Grant OTG-88591 from the Canadian Institutes of Health Research (CIHR). PM received a doctoral bursary from the FRQS. CT was supported by a Senior Scientist Career Award from the FRQS. The above funding organisations had no role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript; or the decision to submit the manuscript for publication.</p></fn><fn fn-type="COI-statement"><p><bold>Competing interests:</bold> None declared.</p></fn><fn fn-type="other"><p><bold>Ethics approval:</bold> Institut Universitaire de G&#x000e9;riatrie de Montr&#x000e9;al Ethics Committee.</p></fn><fn fn-type="other"><p><bold>Provenance and peer review:</bold> Not commissioned; externally peer reviewed.</p></fn><fn fn-type="other"><p><bold>Data sharing statement:</bold> Dataset is available upon request to the corresponding author.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Naganathan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Carter</surname><given-names>SM</given-names></name>, <etal>et al</etal></person-group>
<article-title>Too much medicine in older people? deprescribing through shared decision making</article-title>. <source>BMJ</source>
<year>2016</year>;<volume>353</volume>:<fpage>i2893</fpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmj.i2893">doi:10.1136/bmj.i2893</ext-link>
<pub-id pub-id-type="pmid">27260319</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>IA</given-names></name>, <name name-style="western"><surname>Hilmer</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Reeve</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>
<article-title>Reducing inappropriate polypharmacy: the process of deprescribing</article-title>. <source>JAMA Intern Med</source>
<year>2015</year>;<volume>175</volume>:<fpage>827</fpage>&#x02013;<lpage>34</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jamainternmed.2015.0324">doi:10.1001/jamainternmed.2015.0324</ext-link>
<pub-id pub-id-type="pmid">25798731</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Frank</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Weir</surname><given-names>E</given-names></name></person-group>
<article-title>Deprescribing for older patients</article-title>. <source>CMAJ</source>
<year>2014</year>;<volume>186</volume>:<fpage>1369</fpage>&#x02013;<lpage>76</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1503/cmaj.131873">doi:10.1503/cmaj.131873</ext-link>
<pub-id pub-id-type="pmid">25183716</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Reeve</surname><given-names>E</given-names></name>, <name name-style="western"><surname>To</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hendrix</surname><given-names>I</given-names></name>, <etal>et al</etal></person-group>
<article-title>Patient barriers to and enablers of deprescribing: a systematic review</article-title>. <source>Drugs Aging</source>
<year>2013</year>;<volume>30</volume>:<fpage>793</fpage>&#x02013;<lpage>807</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s40266-013-0106-8">doi:10.1007/s40266-013-0106-8</ext-link>
<pub-id pub-id-type="pmid">23912674</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Woodward</surname><given-names>MC</given-names></name></person-group>
<article-title>Deprescribing: achieving Better Health Outcomes for older people through reducing medications</article-title>. <source>J Pharm Pract Res</source>
<year>2003</year>;<volume>33</volume>:<fpage>323</fpage>&#x02013;<lpage>8</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/jppr2003334323">doi:10.1002/jppr2003334323</ext-link>
</mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Scott</surname><given-names>IA</given-names></name>, <name name-style="western"><surname>Gray</surname><given-names>LC</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>JH</given-names></name>, <etal>et al</etal></person-group>
<article-title>Deciding when to stop: towards evidence-based deprescribing of drugs in older populations</article-title>. <source>Evid Based Med</source>
<year>2013</year>;<volume>18</volume>:<fpage>121</fpage>&#x02013;<lpage>4</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/eb-2012-100930">doi:10.1136/eb-2012-100930</ext-link>
<pub-id pub-id-type="pmid">23136399</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Iyer</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Naganathan</surname><given-names>V</given-names></name>, <name name-style="western"><surname>McLachlan</surname><given-names>AJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>Medication withdrawal trials in people aged 65 years and older: a systematic review</article-title>. <source>Drugs Aging</source>
<year>2008</year>;<volume>25</volume>:<fpage>1021</fpage>&#x02013;<lpage>31</lpage>.<pub-id pub-id-type="pmid">19021301</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Van der Cammen</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>Rajkumar</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Onder</surname><given-names>G</given-names></name>, <etal>et al</etal></person-group>
<article-title>Drug cessation in complex older adults: time for action</article-title>. <source>Age Ageing</source>
<year>2014</year>;<volume>43</volume>:<fpage>20</fpage>&#x02013;<lpage>5</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1093/ageing/aft166">doi:10.1093/ageing/aft166</ext-link>
<pub-id pub-id-type="pmid">24222659</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Declercq</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Petrovic</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Azermai</surname><given-names>M</given-names></name>, <etal>et al</etal></person-group>
<article-title>Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia</article-title>. <source>Cochrane Database Syst Rev</source>
<year>2013</year>;<volume>3</volume>:<fpage>CD007726</fpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/14651858.CD007726.pub2">doi:10.1002/14651858.CD007726.pub2</ext-link>
</mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tamblyn</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>A drug education tool developed for older adults changes knowledge, beliefs and risk perceptions about inappropriate benzodiazepine prescriptions in the elderly</article-title>. <source>Patient Educ Couns</source>
<year>2013</year>;<volume>92</volume>:<fpage>81</fpage>&#x02013;<lpage>7</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.pec.2013.02.016">doi:10.1016/j.pec.2013.02.016</ext-link>
<pub-id pub-id-type="pmid">23541509</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ostini</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Hegney</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Jackson</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>Systematic review of interventions to improve prescribing</article-title>. <source>Ann Pharmacother</source>
<year>2009</year>;<volume>43</volume>:<fpage>502</fpage>&#x02013;<lpage>13</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1345/aph.1L488">doi:10.1345/aph.1L488</ext-link>
<pub-id pub-id-type="pmid">19261953</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tannenbaum</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tamblyn</surname><given-names>R</given-names></name>, <etal>et al</etal></person-group>
<article-title>Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial</article-title>. <source>JAMA Intern Med</source>
<year>2014</year>;<volume>174</volume>:<fpage>890</fpage>&#x02013;<lpage>8</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jamainternmed.2014.949">doi:10.1001/jamainternmed.2014.949</ext-link>
<pub-id pub-id-type="pmid">24733354</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cook</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Biyanova</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Masci</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>Older patient perspectives on long-term anxiolytic benzodiazepine use and discontinuation: a qualitative study</article-title>. <source>J Gen Intern Med</source>
<year>2007</year>;<volume>22</volume>:<fpage>1094</fpage>&#x02013;<lpage>100</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1007/s11606-007-0205-5">doi:10.1007/s11606-007-0205-5</ext-link>
<pub-id pub-id-type="pmid">17492325</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Reeve</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Wiese</surname><given-names>MD</given-names></name>, <name name-style="western"><surname>Hendrix</surname><given-names>I</given-names></name>, <etal>et al</etal></person-group>
<article-title>People<bold>&#x02019;</bold>s attitudes, beliefs, and experiences regarding polypharmacy and willingness to Deprescribe</article-title>. <source>J Am Geriatr Soc</source>
<year>2013</year>;<volume>61</volume>:<fpage>1508</fpage>&#x02013;<lpage>14</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/jgs.12418">doi:10.1111/jgs.12418</ext-link>
<pub-id pub-id-type="pmid">24028356</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pollmann</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Bergman</surname><given-names>JC</given-names></name>, <etal>et al</etal></person-group>
<article-title>Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review</article-title>. <source>BMC Pharmacol Toxicol</source>
<year>2015</year>;<volume>16</volume>:<fpage>19</fpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s40360-015-0019-8">doi:10.1186/s40360-015-0019-8</ext-link>
<pub-id pub-id-type="pmid">26141716</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Westhorp</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Manzano</surname><given-names>A</given-names></name>, <etal>et al</etal></person-group>
<article-title>RAMESES II reporting standards for realist evaluations</article-title>. <source>BMC Med</source>
<year>2016</year>;<volume>14</volume>:<fpage>96</fpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s12916-016-0643-1">doi:10.1186/s12916-016-0643-1</ext-link>
<pub-id pub-id-type="pmid">27342217</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Johansson</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Abuzahra</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Keller</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta-analysis</article-title>. <source>Br J Clin Pharmacol</source>
<year>2016</year>;<volume>82</volume>:<fpage>532</fpage>&#x02013;<lpage>48</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/bcp.12959">doi:10.1111/bcp.12959</ext-link>
<pub-id pub-id-type="pmid">27059768</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Clifford</surname><given-names>RM</given-names></name>, <name name-style="western"><surname>Potter</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>
<article-title>The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis</article-title>. <source>Br J Clin Pharmacol</source>
<year>2016</year>;<volume>82</volume>:<fpage>583</fpage>&#x02013;<lpage>623</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/bcp.12975">doi:10.1111/bcp.12975</ext-link>
<pub-id pub-id-type="pmid">27077231</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Billioti de Gage</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Moride</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ducruet</surname><given-names>T</given-names></name>, <etal>et al</etal></person-group>
<article-title>Benzodiazepine use and risk of Alzheimer<bold>&#x02019;</bold>s disease: case-control study</article-title>. <source>BMJ</source>
<year>2014</year>;<volume>349</volume>:<fpage>g5205</fpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmj.g5205">doi:10.1136/bmj.g5205</ext-link>
<pub-id pub-id-type="pmid">25208536</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal">
<article-title>American Geriatrics Society 2015 Updated Beers Criteria for potentially inappropriate medication use in older adults</article-title>. <source>J Am Geriatr Soc</source>
<year>2015</year>;<volume>63</volume>:<fpage>2227</fpage>&#x02013;<lpage>46</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/jgs.13702">doi:10.1111/jgs.13702</ext-link>
<pub-id pub-id-type="pmid">26446832</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Finkle</surname><given-names>WD</given-names></name>, <name name-style="western"><surname>Der</surname><given-names>JS</given-names></name>, <name name-style="western"><surname>Greenland</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Risk of fractures requiring hospitalization after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults</article-title>. <source>J Am Geriatr Soc</source>
<year>2011</year>;<volume>59</volume>:<fpage>1883</fpage>&#x02013;<lpage>90</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1532-5415.2011.03591.x">doi:10.1111/j.1532-5415.2011.03591.x</ext-link>
<pub-id pub-id-type="pmid">22091502</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Paterniti</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Dufouil</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Alp&#x000e9;rovitch</surname><given-names>A</given-names></name></person-group>
<article-title>Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of vascular aging study</article-title>. <source>J Clin Psychopharmacol</source>
<year>2002</year>;<volume>22</volume>:<fpage>285</fpage>&#x02013;<lpage>93</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1097/00004714-200206000-00009">doi:10.1097/00004714-200206000-00009</ext-link>
<pub-id pub-id-type="pmid">12006899</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Allain</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Bentu&#x000e9;-Ferrer</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Polard</surname><given-names>E</given-names></name>, <etal>et al</etal></person-group>
<article-title>Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review</article-title>. <source>Drugs Aging</source>
<year>2005</year>;<volume>22</volume>:<fpage>749</fpage>&#x02013;<lpage>65</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.2165/00002512-200522090-00004">doi:10.2165/00002512-200522090-00004</ext-link>
<pub-id pub-id-type="pmid">16156679</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cotroneo</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Gareri</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Nicoletti</surname><given-names>N</given-names></name>, <etal>et al</etal></person-group>
<article-title>Effectiveness and safety of hypnotic drugs in the treatment of insomnia in over 70-year old people</article-title>. <source>Arch Gerontol Geriatr</source>
<year>2007</year>;<volume>44</volume>:<fpage>121</fpage>&#x02013;<lpage>4</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1016/j.archger.2007.01.018">doi:10.1016/j.archger.2007.01.018</ext-link>
<pub-id pub-id-type="pmid">17317444</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tannenbaum</surname><given-names>C</given-names></name></person-group>
<article-title>Effect of age, education and health status on community dwelling older men<bold>&#x02019;</bold>s health concerns</article-title>. <source>Aging Male</source>
<year>2012</year>;<volume>15</volume>:<fpage>103</fpage>&#x02013;<lpage>8</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.3109/13685538.2011.626819">doi:10.3109/13685538.2011.626819</ext-link>
<pub-id pub-id-type="pmid">22103599</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tannenbaum</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Mayo</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Ducharme</surname><given-names>F</given-names></name></person-group>
<article-title>Older women<bold>&#x02019;</bold>s health priorities and perceptions of care delivery: results of the WOW health survey</article-title>. <source>CMAJ</source>
<year>2005</year>;<volume>173</volume>:<fpage>153</fpage>&#x02013;<lpage>9</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1503/cmaj.050059">doi:10.1503/cmaj.050059</ext-link>
<pub-id pub-id-type="pmid">16027431</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Stowasser</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Freeman</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis</article-title>. <source>BMJ Open</source>
<year>2014</year>;<volume>4</volume>:<elocation-id>e006544</elocation-id><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmjopen-2014-006544">doi:10.1136/bmjopen-2014-006544</ext-link>
</mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Pawson</surname><given-names>R</given-names></name></person-group>
<source>The science of evaluation: a realist manifestoAIA</source>. <publisher-name>Sage</publisher-name>
<year>2013</year>.</mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Tamblyn</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Ahmed</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>An educational intervention to reduce the use of potentially inappropriate medications among older adults (EMPOWER study): protocol for a cluster randomized trial</article-title>. <source>Trials</source>
<year>2013</year>;<volume>14</volume>:<elocation-id>80</elocation-id><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1745-6215-14-80">doi:10.1186/1745-6215-14-80</ext-link>
<pub-id pub-id-type="pmid">23514019</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Tannenbaum</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>P</given-names></name></person-group>
<source>Sedative-Hypnotic medication De-Prescribing brochure</source>. <publisher-name>Montr&#x000e9;al Iudgd</publisher-name>,<year>2014</year>
<uri xlink:href="http://www.criugm.qc.ca/fichier/pdf/BENZOeng.pdf">http://www.criugm.qc.ca/fichier/pdf/BENZOeng.pdf</uri>
</mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="web">
<person-group person-group-type="author"><name name-style="western"><surname>Hein</surname><given-names>G</given-names></name></person-group>
<article-title>Institute for inquiry constructivist learning theory. Institute for Inquiry available&#x000a0;</article-title>. <year>1991</year>
<uri xlink:href="http://wwwexploratoriumedu/ifi/resources/constructivistlearninghtmlS">http://wwwexploratoriumedu/ifi/resources/constructivistlearninghtmlS</uri>
</mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Festinger</surname><given-names>L</given-names></name></person-group>
<article-title>A Theory of Social comparison processes</article-title>. <source>Human Relations</source>
<year>1954</year>;<volume>7</volume>:<fpage>117</fpage>&#x02013;<lpage>40</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/001872675400700202">doi:10.1177/001872675400700202</ext-link>
</mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Michie</surname><given-names>S</given-names></name>, <name name-style="western"><surname>van Stralen</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>West</surname><given-names>R</given-names></name></person-group>
<article-title>The behaviour change wheel: a new method for characterising and designing behaviour change interventions</article-title>. <source>Implement Sci</source>
<year>2011</year>;<volume>6</volume>:<fpage>42</fpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/1748-5908-6-42">doi:10.1186/1748-5908-6-42</ext-link>
<pub-id pub-id-type="pmid">21513547</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>JW</surname><given-names>C</given-names></name>, <name name-style="western"><surname>P-C</surname><given-names>V</given-names></name></person-group>
<source>Designing and conducting mixed methods research</source>. <publisher-loc>Thousand Oaks, CA</publisher-loc>: <publisher-name>Sage Publications</publisher-name>, <year>2007</year>.</mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Horne</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Weinman</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hankins</surname><given-names>M</given-names></name></person-group>
<article-title>The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication</article-title>. <source>Psychol Health</source>
<year>1999</year>;<volume>14</volume>:<fpage>1</fpage>&#x02013;<lpage>24</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1080/08870449908407311">doi:10.1080/08870449908407311</ext-link>
</mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>B&#x000e9;langer</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Morin</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Bastien</surname><given-names>C</given-names></name>, <etal>et al</etal></person-group>
<article-title>Self-efficacy and compliance with benzodiazepine taper in older adults with chronic insomnia</article-title>. <source>Health Psychol</source>
<year>2005</year>;<volume>24</volume>:<fpage>281</fpage>&#x02013;<lpage>7</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1037/0278-6133.24.3.281">doi:10.1037/0278-6133.24.3.281</ext-link>
<pub-id pub-id-type="pmid">15898864</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>McDowell</surname><given-names>I</given-names></name></person-group>
<source>Measuring health: a guide to rating scales and questionnaires</source>. <edition>3rd ed</edition>
<publisher-loc>New York, NY</publisher-loc>: <publisher-name>Oxford University Press; US</publisher-name>, <year>2006</year>.</mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sandelowski</surname><given-names>M</given-names></name></person-group>
<article-title>Combining qualitative and quantitative sampling, data collection, and analysis techniques in mixed-method studies</article-title>. <source>Res Nurs Health</source>
<year>2000</year>;<volume>23</volume>:<fpage>246</fpage>&#x02013;<lpage>55</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1002/1098-240X(200006)23:3&#x0003c;246::AID-NUR9&#x0003e;3.0.CO;2-H">doi:10.1002/1098-240X(200006)23:3&#x0003c;246::AID-NUR9&#x0003e;3.0.CO;2-H</ext-link>
<pub-id pub-id-type="pmid">10871540</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Ellis</surname><given-names>P</given-names></name></person-group>
<source>The Essential Guide to effect sizes: statistical Power, Meta-Analysis, and the interpretation of Research results</source>. <publisher-loc>Cambridge</publisher-loc>: <publisher-name>Cambridge University Press</publisher-name>, <year>2010</year>.</mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Braun</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Clarke</surname><given-names>V</given-names></name></person-group>
<article-title>Using thematic analysis in psychology</article-title>. <source>Qual Res Psychol</source>
<year>2006</year>;<volume>3</volume>:<fpage>77</fpage>&#x02013;<lpage>101</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1191/1478088706qp063oa">doi:10.1191/1478088706qp063oa</ext-link>
</mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>O&#x02019;Cathain</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Murphy</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Nicholl</surname><given-names>J</given-names></name></person-group>
<article-title>Three techniques for integrating data in mixed methods studies</article-title>. <source>BMJ</source>
<year>2010</year>;<volume>341</volume>:<fpage>c4587</fpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1136/bmj.c4587">doi:10.1136/bmj.c4587</ext-link>
<pub-id pub-id-type="pmid">20851841</pub-id></mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Farmer</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Elliott</surname><given-names>SJ</given-names></name>, <etal>et al</etal></person-group>
<article-title>Developing and implementing a triangulation protocol for qualitative health research</article-title>. <source>Qual Health Res</source>
<year>2006</year>;<volume>16</volume>:<fpage>377</fpage>&#x02013;<lpage>94</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1177/1049732305285708">doi:10.1177/1049732305285708</ext-link>
<pub-id pub-id-type="pmid">16449687</pub-id></mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Prochaska</surname><given-names>J</given-names></name></person-group>
<chapter-title>Transtheoretical Model of Behavior Change</chapter-title> : <person-group person-group-type="editor"><name name-style="western"><surname>Gellman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>JR</given-names></name></person-group>, <source>Encyclopedia of behavioral medicine</source>
<publisher-loc>New York NY</publisher-loc>: <publisher-name>Springer</publisher-name>, <year>2013</year>.</mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>West</surname><given-names>R</given-names></name></person-group>
<article-title>Time for a change: putting the transtheoretical (Stages of Change) Model to rest</article-title>. <source>Addiction</source>
<year>2005</year>;<volume>100</volume>:<fpage>1036</fpage>&#x02013;<lpage>9</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1111/j.1360-0443.2005.01139.x">doi:10.1111/j.1360-0443.2005.01139.x</ext-link>
<pub-id pub-id-type="pmid">16042624</pub-id></mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cassel</surname><given-names>CK</given-names></name>, <name name-style="western"><surname>Guest</surname><given-names>JA</given-names></name></person-group>
<article-title>Choosing wisely: helping physicians and patients make smart decisions about their care</article-title>. <source>JAMA</source>
<year>2012</year>;<volume>307</volume>:<fpage>1801</fpage>&#x02013;<lpage>2</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jama.2012.476">doi:10.1001/jama.2012.476</ext-link>
<pub-id pub-id-type="pmid">22492759</pub-id></mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Sunny</surname><given-names>C</given-names></name>, <name name-style="western"><surname>McDonald</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Landay</surname><given-names>JA</given-names></name></person-group>
<source>Theory-driven design strategies for technologies that support behavior change in everyday life</source>. <publisher-loc>&#x000a0;New York NY</publisher-loc>: <publisher-name>ACM</publisher-name>.</mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Christensen</surname><given-names>LB</given-names></name></person-group>
<source>Educational research: quantitative, qualitative, and mixed approaches</source>. <edition>5th ed</edition>, <year>2014</year>.</mixed-citation></ref><ref id="R48"><label>48.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hilmer</surname><given-names>SN</given-names></name>, <name name-style="western"><surname>Gnjidic</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Le Couteur</surname><given-names>DG</given-names></name></person-group>
<article-title>Thinking through the medication list - appropriate prescribing and deprescribing in robust and frail older patients</article-title>. <source>Aust Fam Physician</source>
<year>2012</year>;<volume>41</volume>:<fpage>924</fpage>.<pub-id pub-id-type="pmid">23210113</pub-id></mixed-citation></ref><ref id="R49"><label>49.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Holmes</surname><given-names>HM</given-names></name>, <name name-style="western"><surname>Todd</surname><given-names>A</given-names></name></person-group>
<article-title>Evidence-based deprescribing of statins in patients with advanced illness</article-title>. <source>JAMA Intern Med</source>
<year>2015</year>;<volume>175</volume>:<fpage>701</fpage>&#x02013;<lpage>2</lpage>.<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1001/jamainternmed.2015.0328">doi:10.1001/jamainternmed.2015.0328</ext-link>
<pub-id pub-id-type="pmid">25799203</pub-id></mixed-citation></ref><ref id="R50"><label>50.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bem</surname><given-names>DJ</given-names></name></person-group>
<article-title>Self-perception: an alternative interpretation of cognitive dissonance phenomena</article-title>. <source>Psychol Rev</source>
<year>1967</year>;<volume>74</volume>:<fpage>183</fpage>&#x02013;<lpage>200</lpage>.&#x02019;<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1037/h0024835">doi:10.1037/h0024835</ext-link>
<pub-id pub-id-type="pmid">5342882</pub-id></mixed-citation></ref><ref id="R51"><label>51.</label><mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dalkin</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Greenhalgh</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Jones</surname><given-names>D</given-names></name>, <etal>et al</etal></person-group>
<article-title>What<bold>&#x02019;</bold>s in a mechanism? development of a key concept in realist evaluation</article-title>. <source>Implement Sci</source>
<year>2015</year>;<volume>10</volume>:<fpage>49</fpage><ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.1186/s13012-015-0237-x">doi:10.1186/s13012-015-0237-x</ext-link>
<pub-id pub-id-type="pmid">25885787</pub-id></mixed-citation></ref><ref id="R52"><label>52.</label><mixed-citation publication-type="book">
<person-group person-group-type="author"><name name-style="western"><surname>Pawson</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Tilley</surname><given-names>N</given-names></name></person-group>
<source>Realistic evaluation</source>. <publisher-loc>London</publisher-loc>: <publisher-name>SAGE</publisher-name>, <year>1997</year>.</mixed-citation></ref></ref-list></back></article>